Journal of Affective Disorders
August 15, 2026
Michał Walaszek, Wiesław Jerzy Cubała, Zofia Kachlik et al.
Anhedonia, a core symptom of major depressive disorder (MDD), is associated with illness severity, suicide risk, poor functioning, and predicts poor response to antidepressants. While no treatments are approved, ketamine and esketamine show promise in reducing anhedonia. This study examines clinical and sociodemographic features linked to anhedonia treatment response in treatment-resistant...
medRxiv
August 14, 2026
Annette M Braxton, Christina Driver, Daniel F. Hermens et al.
preprint
Abstract Major depressive disorder (MDD) and post-traumatic stress disorder (PTSD) are prevalent, chronic, and disabling mental health conditions which are difficult to treat. Ketamine has demonstrated effect for improving depression and PTSD symptoms independently but reports often overlook focused comorbid improvement of these symptoms within individuals. To address this, we assessed...
Neuroscience & Biobehavioral Reviews
August 14, 2026
Subacute and long-term changes in cognitive functioning after administration of classic psychedelics, MDMA and ketamine: A systematic review of clinical and preclinical evidence.
Med
August 13, 2026
Ketamine assisted psychotherapy to reduce chronic neuropathic pain: A mixed-methods randomized pilot trial.
Australian and New Zealand Continence Journal
August 11, 2026
Janine Stirling, M. Doane, M. Simon et al.
Post-traumatic stress disorder places patients at risk for emergence agitation following surgical procedures under general anaesthesia. Gynaecological procedures, sphincteroplasty, and surgical interventions involving the pelvic floor can involve vulnerable patient positioning in theatre, with inserted catheters and sensory stimulation. Such interventions could contribute to postoperative...
European Journal of Endocrinology
August 10, 2026
Huma Humayun Khan, Jeremy Tomlinson
Abstract Ketamine is a dissociative anaesthesia which also has analgesic properties and is also used in pain management and depression1. As it produces an out-of-body and rewarding experience, there is a potential danger for abuse of this medication2.Cystitis and cholangiopathy are recognized side effects of ketamine use3,however, published data on ketamine-induced hyponatremia is scarce.The...
Journal of Affective Disorders
August 10, 2026
Discordant signals: How outcome measurement shapes interpretation of ketamine response in treatment-resistant depression.
Journal of Affective Disorders
August 10, 2026
Intravenous Ketamine reduces psychological pain in suicidal inpatients: A secondary analysis of a six-week randomized placebo-controlled trial.
Journal of Affective Disorders
August 10, 2026
Yves Martins Varela, Patrícia Cavalcanti-Ribeiro, Geovan Menezes de Sousa et al.
BACKGROUND: Ketamine is an effective rapid-acting treatment for treatment-resistant depression (TRD), producing antidepressant effects within hours of administration. Because it induces states of heightened neuroplasticity and psychological openness, psychotherapy may enhance its therapeutic effects. METHODS: This exploratory, nonrandomized, open-label clinical trial evaluated the adjunctive...
Brain Sciences
August 9, 2026
Vikas Chauhan, Fareena Khan
Ketamine produces clinical states ranging from subanesthetic analgesia and dissociation to anesthetic-dose behavioral unresponsiveness. Its electroencephalographic (EEG) effects differ from the slow-delta and frontal-alpha patterns commonly observed with GABAergic-dominant anesthetics and vary with exposure, administration kinetics, and co-administered agents. After anesthetic bolus dosing,...